High proportion of TAFRO syndrome in Thai adult Castleman’s disease patients: a 10-year experience

Weerapat Owattanapanich1 · Wikanda Pholmoo1 · Tawatchai Pongpruttipan2 · Noppadol Siritanaratkul1

Received: 29 December 2017 / Accepted: 31 January 2018 / Published online: 20 February 2018
© The Author(s) 2018. This article is an open access publication

Abstract
Castleman’s disease (CD) is a rare lymphoproliferative disorder, and its prevalence in Thailand is not known. This 10-year period study investigated the prevalence of CD in Thailand, and the clinical characteristics and outcomes of Thai CD patients, with special focus on the existence and prevalence of TAFRO syndrome. TAFRO syndrome is defined as CD with thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly. Thirty-three CD patients diagnosed and treated at Siriraj Hospital during January 2007 to December 2016 were included. The prevalence of CD was 1.4 per 1,000,000 patients/10 years. Median age was 46 years, with slight female predominance. Six patients were assigned to the TAFRO group. A high proportion of TAFRO syndrome (18.2%) was found among Thai adult CD patients. In addition to routine TAFRO diagnostic criteria, significantly lower hemoglobin and albumin levels were observed in the TAFRO group than in the non-TAFRO group. Treatment outcomes of CD patients were complete remission (52%), stable disease (30%), and death (13%). Three-year overall survival in the non-TAFRO group and TAFRO group was 88 and 50%, respectively. While most CD patients had a good prognosis, severe cases with TAFRO syndrome had poor outcome.

Keywords Castleman’s disease · TAFRO syndrome · Lymphadenopathy · Pleural effusion · Ascites

Introduction

Castleman’s disease (CD) or angiofollicular lymph node hyperplasia is a rare lymphoproliferative disorder [1]. A 2014 study from the USA reported an estimated 10-year prevalence of 2.4 cases per one million population [2]. CD involves an abnormal proliferation of cells of the lymphatic system that is similar in many ways to lymphomas, but it is a slowly progressive disease [1]. The pathogenesis of the disease is not known, and diagnosis is based on histopathologic features [3, 4]. Affected lymph nodes are histopathologically classified as hyaline-vascular type (HV), plasma cell variant (PC), or hyaline-vascular-plasma cell type (mixed type) [3]. CD is also clinicopathologically classified as either unicentric CD (UCD) or multicentric CD (MCD) [1]. CD patients usually have no obvious clinical manifestations, with diagnosis usually being made at annual checkup or after investigating mild abnormal symptoms, such as lymphadenopathy and fever. Patient symptoms are characterized by systemic manifestations of inflammation and B cell hyperactivity, such as generalized lymphadenopathies, fever, night sweating, weight loss, and multiple organ involvement, which can resemble autoimmune disease [3, 4]. MCD associated with human herpes virus-8 (HHV-8) or human immunodeficiency virus (HIV) infection that developed in patients with severe inflammation due to overproduction of interleukin-6 (IL-6) was reported in Western countries [3, 5].

In 2012, TAFRO syndrome was defined as CD with thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly [4]. TAFRO syndrome is a systemic inflammatory disorder that occurs in patients with no existing autoimmune diseases. Patients can present with clinical manifestations of bone marrow, pleura, peritoneum, kidney, liver, and lymph node involvement [4, 6]. The definite cause of TAFRO syndrome is currently unknown [4].

Two prior studies in the histopathologic features of CD have been reported from Thailand. A 1997 study reported on 12 cases of CD in Thai patients [7], and a 2002 case report...
profiled a Thai patient with coexisting CD and Kaposi’s sarcoma [8]. However, the prevalence of CD and TAFRO syndrome in Thai population is unknown. Accordingly, this study set forth to investigate the 10-year prevalence of CD in Thailand, and the clinical characteristics and outcomes of Thai CD patients, with special focus on the existence and prevalence of TAFRO syndrome.

Results

The prevalence of CD

A total of 33 cases of CD were identified from 24,082,401 cases that were treated at Siriraj Hospital during the 10-year study period. Our review of pathologic records revealed 99 patients with history of histopathologic diagnosis of CD at our center. Sixty-six of those patients were excluded, as follows: no clinical record and/or were not treated at our hospital (52 patients); re-review of pathology reports revealed findings incompatible with CD (12 patients); and aged less than 15 years (two patients). The remaining 33 cases were included in our exploration and analysis of clinical manifestations and outcomes. The prevalence rate of CD in this study was 0.00014% per 10 years (1.4 per 1,000,000 patients per 10 years; 95% confidence interval (CI) 0.94–1.92).

Clinical characteristics and outcomes of CD patients

Mean age of 33 Thai adult CD patients was 45.7 years (standard deviation 18.6). Gender proportion was 57.6 and 42.4% for women and men, respectively. One-third of patients sought treatment due to lymph node enlargement. Other common clinical manifestations consisted of B symptoms in 42.4% of patients, with 24.2% having weight loss, 27.3% having fever, 6.1% having night sweating, and 15.2% having fatigue. Of the patients who had lymphadenopathy, a majority had generalized lymphadenopathy (72.7%). Just over a quarter of patients had organomegaly, including hepatosplenomegaly (18.2%), hepatomegaly (3%), and splenomegaly (6.1%). The only cardiovascular finding was pericardial effusion in 9.1% of patients. Respiratory symptoms, such as pleural effusion, occurred in 21.2% of cases—all without pleuritic chest pain. Ascites and peritonitis were found in 27.3 and 3% of patients, respectively. Twenty-two percent of patients had proteinuria, but overt renal dysfunction, defined as creatinine clearance less than 60 ml/min/1.73m², was observed in 27.6% of patients. Twelve percent of patients had bone marrow involvement. Overall, 31% of CD patients had multiple organ involvement at first diagnosis.

Most initial laboratory, renal function, liver function, and complete blood count test findings were in normal range, except mean globulin level, which was slightly increased (4.54 g/dl). Nine of 33 patients underwent antinuclear antibody (ANA) testing, with two cases being found positive. Approximately 10% of patients (2/23 patients) were positive for HIV. HHV-8 and EBV tests were performed in four and one cases, respectively, with all five of those cases having a negative result. Histopathologic analysis revealed hyaline-vascular type CD in 18 of 33 cases (54.5%). Plasma cell variant and mixed type was found in 6.1 and 24.2% of cases, respectively. MCD and UCD was found in 75.8 and 24.2% of cases, respectively (Table 1).
Forty percent of patients were closely followed, with no immediate need for treatment. However, 36.7% of patients underwent total excision for diagnosis and treatment. A fifth of surgical patients required chemotherapy or immunosuppressive treatment, including steroid alone/steroid-consisted regimen (23.3%), CVP regimen (10%), rituximab-consisted regimen (6.7%), and CHOP regimen (3.3%). Treatment outcomes included complete remission, stable disease, and death in 52.2, 30.4, and 13% of patients, respectively.

Prevalence and characteristics of TAFRO patients

We identified 6 of 33 patients (18.2%) that satisfied the criteria for TAFRO syndrome, which translates to a prevalence of TAFRO syndrome of 0.000025% per 10 years (0.25 per 1,000,000 patients per 10 years; 95% CI 0.09–0.54).

The demographic and clinical characteristics of TAFRO patients are shown in Table 2. Mean age of TAFRO patients was 44.0 ± 16.3 years, with male predominance (83.3%). All TAFRO syndrome patients had multiple lymphadenopathies, with 66.7 and 80% of cases having intrathoracic and intra-abdominal lymph nodes, respectively. A comparison of baseline characteristics between the TAFRO and non-TAFRO groups revealed a significantly higher rate of pericardial effusion in the TAFRO group ($p = 0.004$). Similarly, rates of B symptoms, pleural effusion, ascites, anasarca, gastrointestinal involvement, proteinuria, and multiple organ involvement were significantly higher in the TAFRO group than in the non-TAFRO group (Table 2).

Laboratory results showed a significant difference for mean hemoglobin between groups (2.7 vs. 3.6 g/dl, respectively; $p = 0.047$). Other laboratory findings were not significantly different between groups (Table 3). Serologic testing revealed that 20% of TAFRO syndrome patients (1/5 patients) were positive for HIV. The most common histopathologic subtype in TAFRO syndrome patients was mixed type (50%).

There were nine patients lost to follow-up after diagnosis or during treatment (seven patients in the non-TAFRO group and two patients in the TAFRO group). Therefore, a total of 24 patients (20 non-TAFRO and 4 TAFRO) were evaluated for treatment response (Fig. 1). Twenty percent of patients (5/25 patients) in the non-TAFRO group and 40% of patients (2/5 patients) in the TAFRO group required chemotherapy and immunosuppressive agent ($p = 0.565$). Treatment of TAFRO syndrome included rituximab-based regimen (20%), CHOP regimen (20%), and CVP regimen (20%). Treatment outcomes were partial response, stable disease, and death in 25, 25, and 50% of patients, respectively. No patient had complete response. Three-year overall survival in the non-TAFRO group and TAFRO group was 88 and 50%, respectively ($p = 0.125$).

Discussion

TAFRO syndrome was first described in 2009 [4], and revised diagnostic criteria for this disorder were proposed in 2012 and 2015 [4, 9]. While many studies in CD and TAFRO syndrome have been published, this is the first study to describe the prevalence, clinical characteristics, and outcomes of adult CD patients in Thailand. Moreover, 6 of the 33 patients that we identified with CD also satisfied the 2009 diagnostic criteria for TAFRO syndrome.
The prevalence of CD in this study was 1.4 per 1,000,000 patients per 10 years. Median age of CD patients was 46 years. A prior Western systematic analysis found a median age of 33 and 38 years for females and males, respectively [10]. In the present study, CD was more common in women than men (57.6 vs. 42.4%), which is similar to prior study [4]. Nearly half of our patients sought treatment due to lymph node enlargement. Most CD patients in this study had no hepatosplenomegaly, while all 6 TAFRO syndrome patients had hepatomegaly and/or splenomegaly. Multiple organ involvement was found in 31.3% of CD patients, to include pericardial effusion, cardiomegaly, pleural effusion, ascites, peritonitis, proteinuria, and renal dysfunction. Regarding bone marrow involvement, 16.7% of CD patients were found to be affected at first diagnosis.

In this study, immunologic testing was not frequently performed. Serologic testing, especially anti-HIV testing, was performed in 23 cases. Two (8.7%) of those patients tested positive for HIV, which was similar to the 7.7% rate reported in a 2011 Western study [10]. Histopathologic analysis found hyaline-vascular type to be the most common subtype (64.3%), which was consistent with previous study (58%) [10]. In contrast, centricity results between this study and previous study varied.

| Table 1 | Immunology, serology, histopathology, centricity, and treatment outcomes in 33 Thai Castleman’s disease patients |
|--------|-----------------------------------------------|
| Serology testing |  n | Positive (%) | Negative (%) | Not performed (%) |
| HHV-8 | 4 | 0.0 | 12.1 | 87.9 |
| HIV | 23 | 6.1 (n = 2) | 63.6 | 30.3 |
| EBV | 1 | 0.0 | 3.2 | 96.8 |
| Histopathology type | n | Valid percentage (%) |
| HV type | 18 | 54.5 |
| PC type | 2 | 6.1 |
| Mixed type | 8 | 24.2 |
| Type not identified | 5 | 15.2 |
| Centricity | n | Valid percentage (%) |
| Unicentricity | 8 | 24.2 |
| Multicentricity | 25 | 75.8 |
| Treatment | n | Valid percentage (%) |
| Treatment | 16 | 53.3 |
| Chemotherapy | 7 | 23.3 |
| -Steroid alone/steroid-consisted regimen | 7 | 23.3 |
| -Rituximab-consisted regimen | 2 | 6.7 |
| -CHOP regimen | 1 | 3.3 |
| -CVP regimen | 3 | 10.0 |
| Surgery | 11 | 36.7 |
| Watchful waiting | 12 | 40.0 |
| Response | n | Valid percentage (%) |
| Complete remission | 12 | 52.2 |
| Partial remission | 1 | 4.3 |
| Stable disease | 7 | 30.4 |
| Death | 3 | 13.0 |
| Loss to follow-up | 14 | 58.3 |
| Follow-up duration (months), median (range) | 8.77 (0.07 to 97.41) |
| Three-year overall survival (%) | 82.0 |
| Castleman’s disease | n = 33 | 100% |
| TAFRO syndrome (2009) | 6 | 18.2 |
| Non-TAFRO syndrome (2009) | 27 | 81.8 |
| TAFRO syndrome (2012) | 5 | 15.2 |
| Non-TAFRO syndrome (2012) | 28 | 84.8 |
Table 2 Demographic and clinical characteristics compared between Thai Castleman’s disease patients with and without TAFRO syndrome

|                        | CD without TAFRO syndrome (n = 27) | CD with TAFRO syndrome (n = 6) | p value | OR (95% CI) |
|------------------------|------------------------------------|--------------------------------|---------|-------------|
| Positive results (%)   | Positive results (%)                |                                |         |             |
| Gender                 |                                    |                                | 0.062   |             |
| Male                   | 33.3%                              | 83.3%                          |         |             |
| Female                 | 66.7%                              | 16.7%                          |         |             |
| Age (years), mean ± SD |                                    |                                | 0.813   |             |
| Clinical presentation  |                                    |                                |         |             |
| Palpable mass (lymph node) | 40.7%                          | 0.0%                          | 0.077   |             |
| Edema                  | 7.4%                               | 0.0%                           |         |             |
| Fever                  | 0.0%                               | 66.7%                          |         |             |
| Fatigue                | 3.7%                               | 33.3%                          |         |             |
| B symptoms             |                                    |                                | 0.003   | N/A         |
| Weight loss            | 29.6%                              | 100%                           | 0.296   |             |
| Fever                  | 11.1%                              | 100%                           | < 0.001 | N/A         |
| Night sweating         | 7.4%                               | 0.0%                           | 1       |             |
| Fatigue                | 7.4%                               | 50.0%                          | 0.031   | 12.5 (1.45–107.63) |
| Lymphadenopathy        |                                    |                                | 0.296   |             |
| Superficial LN         | 100%                               | 100%                           |         |             |
| Infrathoracic LN       | 51.9%                              | 50.0%                          | 1       |             |
| Intra-abdominal LN     | 55.6%                              | 66.7%                          | 1       |             |
| Single LN              | 6.9%                               | 80.0%                          | 0.628   |             |
| Multiple LN            | 33.3%                              | 100%                           | 0.156   |             |
| Organomegaly           | 15.0%                              | 100%                           | 0.838   |             |
| Hepatomegaly           | 0.0%                               | 16.7%                          |         |             |
| Splenomegaly           | 7.4%                               | 0.0%                           |         |             |
| Hepatosplenomegaly     | 3.7%                               | 83.3%                          |         |             |
| Multiple organ involvement | 15.4%                          | 100%                           | < 0.001 | N/A         |
| Cardiovascular system  |                                    |                                | 0.031   | 12.5 (1.45–107.63) |
| Cardiomegaly           | 7.4%                               | 50.0%                          | 0.464   |             |
| Pericardial effusion   | 7.4%                               | 16.7%                          | 0.004   | N/A         |
| Respiratory            | 0.0%                               | 50.0%                          |         |             |
| Pleural effusion       | 30.0%                              | 50.0%                          | 0.06    |             |
| Pleuritis              | 7.4%                               | 83.3%                          | < 0.001 | 62.5 (4.71–829.3) |
| Gastrointestinal system|                                    |                                | 0.001   | N/A         |
| Ascites                | 22.2%                              | 100%                           | < 0.001 | N/A         |
| Peritonitis            | 11.1%                              | 100%                           | < 0.001 | N/A         |
| Renal system           |                                    |                                | 0.025   | 11.88 (1.19–118.5) |
| Proteinuria            |                                    |                                | 0.001   | 60 (4.52–797.1) |
| Renal dysfunction      |                                    |                                | 0.597   |             |
| Anasarca               |                                    |                                | 0.001   | N/A         |
| Bone marrow involvement|                                    |                                | 0.559   |             |
| Myelofibrosis          |                                    |                                | 0.001   | N/A         |
| Stage                  |                                    |                                | < 0.001 | N/A         |
| Stage I                | 29.6%                              | 0.0%                           |         |             |
| Stage II               | 44.4%                              | 0.0%                           |         |             |
| Stage III              | 18.5%                              | 0.0%                           |         |             |
| Stage IV               | 7.4%                               | 100%                           |         |             |

A p value < 0.05 indicates statistical significance.

CD Castleman’s disease, CI confidence interval, SD standard deviation, LN lymph node, N/A not applicable.
widely. UCD was found in 24.2% of cases in this study, as compared to the 73.7% rate reported by Talat and Schulte [10].

Regarding treatment, 40% of patients did not require immediate treatment, but they were closely followed. Twenty-three percent of patients required chemotherapy or immunosuppressive treatment that included steroid alone/steroid-consisted regimen, CVP regimen, rituximab, and/or CHOP regimen, which was similar to the treatment regimens prescribed in previous studies [11–14]. The treatment outcomes were complete remission, stable disease, and death in about 52, 30, and 13% of cases, respectively, which was similar to the 15% mortality rate reported in a previous study [10].

Studies from Japan defined CD with severe symptoms as TAFRO syndrome in 2009 and 2012 [4,14]. Six of 33 CD patients in this study satisfied the 2009 diagnostic criteria for TAFRO syndrome. Interestingly, the proportion of TAFRO syndrome in CD patients in the present study was higher than the proportion in a previous study [18.2% (6/33) patients vs. 0.7% (2/273) patients, respectively] [15]. The data permits us to postulate that Asian population are more prone to developing severe CD (TAFRO syndrome) than Western population [1, 4–6, 9, 12–14]. The median age of CD with TAFRO syndrome was 44 years with male predominance, which was different from a Japanese study that found a median age of 56 years with female predominance [4]. All patients with CD and TAFRO syndrome in this study had B symptoms, multiple lymphadenopathies, anasarca, and multiple organ involvement. Notably—in addition to meeting the diagnostic criteria for TAFRO syndrome, significantly lower hemoglobin and lower albumin levels were shown in the TAFRO group than in the non-TAFRO group in this study. We prefer to use the 2009 criteria for TAFRO diagnosis, because it has higher sensitivity for detecting TAFRO cases than the 2012 and 2015 criteria. Furthermore, the 2012 and 2015 criteria failed to detect some severe cases of CD that ended up having a poor treatment outcome.

Treatment regimens of TAFRO syndrome patients in this study included chemotherapy and immunosuppressive agent (40%), chemotherapy and immunosuppressive agent containing rituximab-consisted regimen (20%), CHOP regimen (20%), and CVP regimen (20%). Treatment outcomes were partial response (25%), stable disease (25%), and death (50%). No TAFRO patient had complete response. In this study, the prognosis of TAFRO syndrome patients was clearly worse than the prognosis of CD patients.

This study has some mentionable limitations. First, due to the rarity of this disorder, the size of our study population was

| Table 3 | Age, laboratory, immunology, serology, histopathology, centricity, and treatment outcomes compared between Thai Castleman’s disease patients with and without TAFRO syndrome |
|---|---|---|---|---|---|---|---|
| | CD without TAFRO syndrome | CD with TAFRO syndrome | p value |
| | n | Mean ± SD | Median | 25th/75th percentile | Min-max | n | Mean ± SD | Median | 25th/75th percentile | Min-max |
| Age (years) | 27 | 46 ± 19.4 | | | | 6 | 44 ± 16.3 | | | | | 0.813 |
| Hb (g/dl) | 27 | 11.7 ± 2.4 | | | | 6 | 9.2 ± 1.7 | | | | | 0.025 |
| Plt (x10^3/mcl) | 27 | 294.2 ± 143.4 | | | | 6 | 171 | 93/259 | 46–363 | | 0.095 |
| Alb (mg/l) | 23 | 3.6 ± 0.9 | | | | 6 | 2.7 ± 1 | | | | | 0.047 |
| LDH (U/l) | 16 | 280.9 ± 128.5 | | | | 5 | 401.6 ± 122.1 | | | | | 0.058 |
| BUN (mg/dl) | 24 | 11 | 9.8/16.8 | 7.9–38 | | 6 | 16.6 | 11.7/33 | 9–51.2 | | 0.153 |
| Cr (mg/dl) | 25 | 1.0 ± 0.4 | | | | 6 | 1.0 ± 0.3 | | | | | 0.564 |
| GFR (ml/min/1.73m^2) | 23 | 81.8 | 47/100 | 23–250 | | 6 | 69.9 ± 25.7 | | | | | 0.418 |
| Response | CD without TAFRO syndrome | CD with TAFRO syndrome | p value |
| Positive (%) | (12/20) 60% | (0/4) 0% | 0.016 |
| (0/20) 0% | (1/4) 25% |
| (5/20) 25% | (1/4) 25% |
| (3/20) 13% | (2/4) 50% |
| Three-year overall survival (%) | 88% | 50% | 0.125 |

A p value < 0.05 indicates statistical significance

CD Castleman’s disease, SD standard deviation, Hb hemoglobin, Plt platelet, Alb albumin, LDH lactate dehydrogenase, BUN blood urea nitrogen, Cr creatinine, GFR glomerular filtration rate, CR complete response, PR partial response, SD stable disease
relatively small. As a result, our study may have lacked sufficient power to identify all significant associations. Second, our center is Thailand’s largest tertiary referral hospital, which means that we are often referred patients with complicated and intransigent conditions. As such, it is possible that the prevalence rate of CD in this study might be higher than the prevalence rate in general population.

**Conclusion**

The prevalence of CD in Thailand is very low; however, a high proportion of TAFRO syndrome was found in Thai adult CD patients compared to a previous study. Although most CD patients had a good prognosis, severe cases with TAFRO syndrome had poor outcome.

**Acknowledgements** The authors gratefully acknowledge Prof. Dr. Med. Peter Hokland for consultation and support, Ms. Phensri Niamyin for organizing the processing and review of tissue specimens, and Ms. Khemaja Karak踢klang for assistance with statistical analysis.

**Authors’ contributions** WP and WO designed the study, collected the data, performed statistical analysis, and drafted the manuscript. NS and WO supervised the project and made critical revisions to the manuscript. TP reviewed tissue samples to confirm diagnosis and subtype. All authors read and approved the final manuscript.

**Compliance with ethical standards**

All procedures were conducted in accordance with the ethical standards of the responsible committee on human experimentation, and in accordance with the 1964 Declaration of Helsinki and all of its subsequent revisions. The local ethical commission approved the study (COA no. Si 062/2016, Siriraj Hospital, Mahidol University, Bangkok, Thailand). Written informed consent was waived, given the retrospective nature of this study.

**Conflict of interests** The authors declare that they have no conflict of interest.

**Consent for publication** A copy of the consent document is available for review by the Editor-in-Chief of Annals of Hematology.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Iwaki N, Sato Y, Takata K, Kondo E, Ohno K, Takeuchi M, Orita Y, Nakao S, Yoshino T (2013) Atypical hyaline vascular-type castelman’s disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy. J Clin Exp Hematop 53(1):87–93. https://doi.org/10.3960/jslrt.53.87

2. Robinson D Jr, Reynolds M, Casper C, Dispensieri A, Vermeulen J, Payne K, Schramm J, Ristow K, Desrosiers MP, Yeomans K, Teltsch D, Swain R, Habermann TM, Rotella P, van de Velde H (2014) Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres. Br J Haematol 165(1):39–48. https://doi.org/10.1111/bjh.12717

3. Muzes G, Sipos F, Csomor J, Sreter L (2013) Multicentric Castelman’s disease: a challenging diagnosis. Pathol Oncol Res 19(3):345–351. https://doi.org/10.1007/s12253-013-9619-9

4. Kawabata H, Takai K, Kojima M, Nakamura N, Aoki S, Nakamura S, Kinoshita T, Masaki Y (2013) Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), macrocytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (June 6, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop 53(1):57–61

5. Masaki Y, Nakajima A, Iwao H, Kurose N, Sato T, Nakamura T, Miki M, Sakai T, Kawanami T, Sawaki T, Fujita Y, Tanaka M, Fukushima T, Okazaki T, Umehara H (2013) Japanese variant of multicentric castleman’s disease associated with serositis and thrombocytopenia—a report of two cases: is TAFRO syndrome (Castleman-Kojima disease) a distinct clinicopathological entity? J Clin Exp Hematop 53(1):79–85. https://doi.org/10.3960/jslrt.53.79

6. Kubokawa I, Yachie A, Hayakawa A, Hirase S, Yamamoto N, Mori T, Yanai T, Takeshirina Y, Kyo E, Kageyama G, Nagai H, Uehara K, Kojima M, Iijima K (2014) The first report of adolescent TAFRO syndrome, a unique clinicopathological variant of multicentric Castelman’s disease. BMC Pediatr 14(1):139. https://doi.org/10.1186/1471-2431-14-139

7. Kasantikul V, Panyavoravut V, Benjavongkulchai S, Panichabhongse V (1997) Castleman’s disease: a clinicopathologic study of 12 cases. J Med Assoc Thai 80(3):195–201

8. Sukapanichnant S, Sivayathorn S, Ngowthammatas W (2002) Multicentric Castleman’s disease, non-Hodgkin’s lymphoma, and Kaposi’s sarcoma: a rare simultaneous occurrence. Asian Pac J Allergy Immunol 20(2):127–133

9. Masaki Y, Kawabata H, Takai K, Kojima M, Tsukamoto N, Ishigaki Y, Kurose N, Ide M, Murakami J, Nara K, Yamamoto H, Ozawa Y, Takahashi H, Miura K, Miyauchi T, Yoshida S, Momoi A, Awan O, Ikushima S, Ohta Y, Furuta N, Fujimoto S, Kawanami H, Sakai T, Kawanami T, Fujita Y, Fukushima T, Nakamura S, Kinoshita T, Aoki S (2016) Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol 103(6):686–692. https://doi.org/10.1007/s12185-016-1979-4

10. Talat N, Schulte KM (2011) Castleman’s disease: systemic analysis of 416 patients from the literature. Oncologist 16(9):1316–1324. https://doi.org/10.1634/theoncologist.2011-0075

11. Tedesco S, Postacchini L, Manfredi L, Goteri G, Luchetti MM, Cappiello F, Gabrielli A, Pomponio G (2015) Successful treatment of TAFRO syndrome, a variant of multicentric Castleman’s disease associated with serositis and thrombocytopenia using tocilizumab, an anti-interleukin-6 receptor antibody. Intern Med 52(13):1503–1507. https://doi.org/10.2169/internalmedicine.52.9482

12. Kawabata H, Kotani S, Matsumura Y, Kondo T, Katsurada T, Haga H, Kadowaki N, Takaori-Kondo A (2013) Successful treatment of a patient with multicentric Castleman’s disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody. Intern Med 52(13):1503–1507. https://doi.org/10.2169/internalmedicine.52.9482

13. Konishi Y, Takahashi S, Nishi K, Sakamaki T, Mitani S, Kaneko H, Mizutani C, Ukyo N, Hirata H, Tsado M (2015) Successful treatment of TAFRO syndrome, a variant of multicentric Castleman’s disease, with cyclosporine a: possible pathogenetic contribution of interleukin-2. Tohoku J Exp Med 236(4):289–295. https://doi.org/10.1620/tjem.236.289
14. Inoue M, Ankou M, Hua J, Iwaki Y, Hagihara M, Ota Y (2013) Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin A: a case report. J Clin Exp Hematop 53(1):95–99. https://doi.org/10.3960/jslrt.53.95

15. Oksenhendler E, Boutboul D, Fajgenbaum D, Mirouse A, Fieschi C, Malphettes M, Vercellino L, Meignon V, Gérard L, Galicier L (2017) The full spectrum of Castleman disease: 273 patients studied over 20 years. Br J Haematol 180(2):206–216. https://doi.org/10.1111/bjh.15019